logo
  

Burning Rock, Merck KGaA Collaborate On Liquid-biopsy Based CDx Development Using OncoCompass Target

Burning Rock Biotech Limited (BNR) said that it has partnered with Merck KGaA, in companion diagnostics or CDx development for the MET inhibitor tepotinib in the mainland China market.

The CDx test is based on Burning Rock's self-developed next generation sequencing (NGS)-based liquid biopsy solution, OncoCompass Target panel.

Tepotinib is an oral MET inhibitor that inhibits the oncogenic MET receptor signaling caused by MET (gene) alterations. Discovered and developed in-house at Merck KGaA, tepotinib has a highly selective mechanism of action, with the potential to improve outcomes in aggressive tumors that have a poor prognosis and harbor these specific alterations.

Tepotinib was the first oral MET inhibitor to receive a regulatory approval anywhere in the world for the treatment of advanced non-small cell lung cancer (NSCLC) harboring MET gene alterations, with its approval in Japan in March 2020 under the brand name TEPMETKO.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Nestle Purina PetCare Co. has recalled a limited amount of certain prescription wet dog food citing labeling error, the U.S. Food and Drug Administration said. The recall involves Purina Pro Plan Veterinary Diets EN Gastroenteric Low Fat or PPVD EN Low Fat wet dog food that comes in 13.4 oz cans. Exportadora Copramar is recalling 1260 cases of James Farm frozen raspberries citing potential to be contaminated with Hepatitis A, the U.S. Food and Drug Administration said. The recall involves James Farm branded frozen raspberries identified by UPC Code: 76069501010 and Lot Code - 22-165. American Honda Motor Co, Inc. has recalled about 2,900 units of 2022 model year Honda TRX90X All-Terrain Vehicles (ATVs) sold in the United States for possible crash and injury hazard, according to a statement issued by the U.S. Consumer Product Safety Commission or CPSC.
Follow RTT